181 related articles for article (PubMed ID: 37573025)
41. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
[TBL] [Abstract][Full Text] [Related]
42. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
[TBL] [Abstract][Full Text] [Related]
43. Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer.
Lee YC; Bressel M; Grant P; Russell P; Smith C; Picken S; Camm S; Kiely BE; Milne RL; McLachlan SA; Hickey M; Friedlander ML; Hopper JL; Phillips KA;
Fam Cancer; 2017 Oct; 16(4):461-469. PubMed ID: 28285341
[TBL] [Abstract][Full Text] [Related]
44. Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.
Rabban JT; Crawford B; Chen LM; Powell CB; Zaloudek CJ
Am J Surg Pathol; 2009 Jan; 33(1):111-9. PubMed ID: 18830124
[TBL] [Abstract][Full Text] [Related]
45. Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers.
Reitsma W; Mourits MJ; de Bock GH; Hollema H
Mod Pathol; 2013 Apr; 26(4):572-8. PubMed ID: 23080033
[TBL] [Abstract][Full Text] [Related]
46. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
[TBL] [Abstract][Full Text] [Related]
47. Incidental Serous Tubal Intraepithelial Carcinoma that Developed into Primary Peritoneal Serous Carcinoma in a Patient without BRCA Mutation.
Chong GO; Park JY; Lee HJ
Am J Case Rep; 2020 Feb; 21():e921146. PubMed ID: 32034117
[TBL] [Abstract][Full Text] [Related]
48. Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
Grandi G; Sammarini M; Cortesi L; Toss A; Botticelli L; Varliero F; Sighinolfi G; Barbieri E; Facchinetti F
Menopause; 2021 Feb; 28(3):263-270. PubMed ID: 33534430
[TBL] [Abstract][Full Text] [Related]
49. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
[TBL] [Abstract][Full Text] [Related]
50. Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
Straub MM; Podoll MB; David SN; Wiesner GL; Desouki MM
Ann Diagn Pathol; 2018 Oct; 36():28-30. PubMed ID: 30055521
[TBL] [Abstract][Full Text] [Related]
51. Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
Crosbie EJ; Flaum N; Harkness EF; Clayton RD; Holland C; Martin-Hirsch P; Wood N; Keating P; Woodward ER; Lalloo F; Donnai P; Edmondson RJ; Evans DG
Int J Cancer; 2021 Mar; 148(5):1155-1163. PubMed ID: 33152107
[TBL] [Abstract][Full Text] [Related]
52. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.
Sherman ME; Piedmonte M; Mai PL; Ioffe OB; Ronnett BM; Van Le L; Ivanov I; Bell MC; Blank SV; DiSilvestro P; Hamilton CA; Tewari KS; Wakeley K; Kauff ND; Yamada SD; Rodriguez G; Skates SJ; Alberts DS; Walker JL; Minasian L; Lu K; Greene MH
J Clin Oncol; 2014 Oct; 32(29):3275-83. PubMed ID: 25199754
[TBL] [Abstract][Full Text] [Related]
53. Clinical background and outcomes of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancers in Japan.
Nomura H; Sekine M; Yokoyama S; Arai M; Enomoto T; Takeshima N; Nakamura S
Int J Clin Oncol; 2019 Sep; 24(9):1105-1110. PubMed ID: 31055694
[TBL] [Abstract][Full Text] [Related]
54. Prophylactic Bilateral Salpingo-oophorectomy in BRCA2 Mutation with Incidental Finding of Serous Tubal Intraepithelial Carcinoma (STIC) and Subsequent Diagnosis of Primary Peritoneal Carcinoma (PPC): A Case Report and Review of Current Literature.
Palaiologos K; Ellaboudy A; Abdullah M; Karan S; Saha A
Cureus; 2020 Jul; 12(7):e9301. PubMed ID: 32832298
[TBL] [Abstract][Full Text] [Related]
55. LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions.
Schmoeckel E; Odai-Afotey AA; Schleißheimer M; Rottmann M; Flesken-Nikitin A; Ellenson LH; Kirchner T; Mayr D; Nikitin AY
Mod Pathol; 2017 Sep; 30(9):1241-1250. PubMed ID: 28664938
[TBL] [Abstract][Full Text] [Related]
56. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
57. Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers.
Cowan R; Nobre SP; Pradhan N; Yasukawa M; Zhou QC; Iasonos A; Soslow RA; Arnold AG; Trottier M; Catchings A; Roche KL; Gardner G; Robson M; Abu Rustum NR; Aghajanian C; Cadoo K
Gynecol Oncol; 2021 May; 161(2):521-526. PubMed ID: 33712278
[TBL] [Abstract][Full Text] [Related]
58. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.
Yates MS; Meyer LA; Deavers MT; Daniels MS; Keeler ER; Mok SC; Gershenson DM; Lu KH
Cancer Prev Res (Phila); 2011 Mar; 4(3):463-70. PubMed ID: 21278312
[TBL] [Abstract][Full Text] [Related]
59. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
Steenbeek MP; Harmsen MG; Hoogerbrugge N; de Jong MA; Maas AHEM; Prins JB; Bulten J; Teerenstra S; van Bommel MHD; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JMJ; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Massuger LFAG; IntHout J; Hermens RPMG; de Hullu JA
JAMA Oncol; 2021 Aug; 7(8):1203-1212. PubMed ID: 34081085
[TBL] [Abstract][Full Text] [Related]
60. Incidence and Characteristics of Unsuspected Neoplasia Discovered in High-Risk Women Undergoing Risk Reductive Bilateral Salpingooophorectomy.
Poon C; Hyde S; Grant P; Newman M; Ireland Jenkin K
Int J Gynecol Cancer; 2016 Oct; 26(8):1415-20. PubMed ID: 27488216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
